Mari Michele Nakamura, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-Infective Agents | 3 | 2024 | 983 | 1.360 |
Why?
|
| Hospitals, Pediatric | 9 | 2023 | 1859 | 1.290 |
Why?
|
| Antiviral Agents | 6 | 2024 | 3037 | 1.260 |
Why?
|
| Influenza, Human | 4 | 2023 | 1521 | 0.860 |
Why?
|
| Patient Readmission | 7 | 2018 | 3269 | 0.810 |
Why?
|
| Orbital Cellulitis | 1 | 2022 | 33 | 0.790 |
Why?
|
| Anti-Bacterial Agents | 11 | 2024 | 7403 | 0.760 |
Why?
|
| Staphylococcal Infections | 3 | 2022 | 1406 | 0.720 |
Why?
|
| Meningitis, Bacterial | 1 | 2022 | 221 | 0.690 |
Why?
|
| Influenza Vaccines | 2 | 2022 | 767 | 0.660 |
Why?
|
| Community-Acquired Infections | 3 | 2024 | 469 | 0.640 |
Why?
|
| Urinary Tract Infections | 1 | 2024 | 802 | 0.590 |
Why?
|
| Streptococcal Infections | 1 | 2022 | 617 | 0.590 |
Why?
|
| Fluoroquinolones | 1 | 2018 | 306 | 0.530 |
Why?
|
| Child | 33 | 2024 | 80089 | 0.510 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2022 | 697 | 0.510 |
Why?
|
| Quality Indicators, Health Care | 5 | 2018 | 1790 | 0.500 |
Why?
|
| Bacterial Infections | 2 | 2021 | 1389 | 0.450 |
Why?
|
| Communicable Diseases | 1 | 2022 | 871 | 0.440 |
Why?
|
| Carrier State | 2 | 2010 | 522 | 0.430 |
Why?
|
| Staphylococcus aureus | 3 | 2022 | 1457 | 0.420 |
Why?
|
| Reimbursement, Incentive | 2 | 2015 | 542 | 0.420 |
Why?
|
| Diffusion of Innovation | 2 | 2015 | 729 | 0.420 |
Why?
|
| Pneumonia, Viral | 2 | 2021 | 3209 | 0.420 |
Why?
|
| Electronic Health Records | 4 | 2023 | 4810 | 0.390 |
Why?
|
| Bronchiolitis | 1 | 2017 | 485 | 0.370 |
Why?
|
| Immunization | 2 | 2022 | 1217 | 0.360 |
Why?
|
| Antibodies, Monoclonal | 3 | 2023 | 9171 | 0.360 |
Why?
|
| Pneumonia | 2 | 2024 | 2143 | 0.350 |
Why?
|
| Outpatients | 1 | 2018 | 1596 | 0.340 |
Why?
|
| Bacteriological Techniques | 1 | 2010 | 275 | 0.320 |
Why?
|
| Infant | 12 | 2024 | 36157 | 0.300 |
Why?
|
| Pharynx | 1 | 2010 | 432 | 0.290 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2017 | 1187 | 0.290 |
Why?
|
| Quality Assurance, Health Care | 2 | 2014 | 2164 | 0.290 |
Why?
|
| Child, Preschool | 13 | 2024 | 42193 | 0.280 |
Why?
|
| Bordetella pertussis | 1 | 2006 | 45 | 0.280 |
Why?
|
| Medicaid | 2 | 2017 | 2814 | 0.270 |
Why?
|
| Adolescent | 17 | 2024 | 88247 | 0.270 |
Why?
|
| Patient Access to Records | 1 | 2007 | 119 | 0.270 |
Why?
|
| Nose | 1 | 2010 | 521 | 0.270 |
Why?
|
| Medical Records Systems, Computerized | 2 | 2015 | 1191 | 0.270 |
Why?
|
| Decision Support Systems, Clinical | 2 | 2023 | 1171 | 0.260 |
Why?
|
| Medical Informatics | 1 | 2013 | 732 | 0.260 |
Why?
|
| Practice Guidelines as Topic | 1 | 2022 | 7390 | 0.240 |
Why?
|
| Emergency Service, Hospital | 1 | 2024 | 7873 | 0.230 |
Why?
|
| Research Design | 1 | 2020 | 6174 | 0.230 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 7995 | 0.230 |
Why?
|
| Vaccination | 2 | 2022 | 3370 | 0.220 |
Why?
|
| Immunocompromised Host | 3 | 2022 | 858 | 0.210 |
Why?
|
| Retrospective Studies | 15 | 2024 | 80583 | 0.210 |
Why?
|
| Quality Improvement | 3 | 2014 | 3801 | 0.210 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3088 | 0.200 |
Why?
|
| Humans | 40 | 2024 | 760740 | 0.200 |
Why?
|
| Methicillin Resistance | 1 | 2002 | 198 | 0.190 |
Why?
|
| Health Care Surveys | 3 | 2015 | 2422 | 0.190 |
Why?
|
| Streptococcus agalactiae | 1 | 2022 | 337 | 0.180 |
Why?
|
| Twins, Monozygotic | 1 | 2022 | 470 | 0.180 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2006 | 1131 | 0.180 |
Why?
|
| Hospitals | 4 | 2024 | 3879 | 0.180 |
Why?
|
| Ceftriaxone | 1 | 2021 | 175 | 0.170 |
Why?
|
| Feedback | 1 | 2024 | 790 | 0.170 |
Why?
|
| Pediatrics | 4 | 2020 | 3589 | 0.170 |
Why?
|
| Aspergillosis | 1 | 2022 | 242 | 0.170 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2022 | 755 | 0.170 |
Why?
|
| Nasopharynx | 1 | 2002 | 400 | 0.170 |
Why?
|
| Adenosine Monophosphate | 1 | 2021 | 231 | 0.160 |
Why?
|
| Vancomycin | 1 | 2022 | 503 | 0.160 |
Why?
|
| Osteomyelitis | 1 | 2023 | 407 | 0.160 |
Why?
|
| Abscess | 1 | 2022 | 606 | 0.150 |
Why?
|
| Alanine | 1 | 2021 | 609 | 0.150 |
Why?
|
| Quality of Health Care | 1 | 2013 | 4325 | 0.150 |
Why?
|
| Blood Cell Count | 1 | 2018 | 397 | 0.140 |
Why?
|
| Seizures | 2 | 2022 | 2964 | 0.140 |
Why?
|
| Infant, Newborn | 5 | 2022 | 26183 | 0.140 |
Why?
|
| Aspartate Aminotransferases | 1 | 2018 | 414 | 0.140 |
Why?
|
| Bilirubin | 1 | 2018 | 435 | 0.130 |
Why?
|
| Drug Combinations | 1 | 2022 | 2048 | 0.130 |
Why?
|
| Comorbidity | 3 | 2024 | 10507 | 0.130 |
Why?
|
| Trust | 1 | 2020 | 529 | 0.130 |
Why?
|
| Alanine Transaminase | 1 | 2018 | 601 | 0.130 |
Why?
|
| Societies, Hospital | 1 | 2015 | 6 | 0.130 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 619 | 0.130 |
Why?
|
| Risk Factors | 9 | 2024 | 74128 | 0.130 |
Why?
|
| Hospitals, Community | 1 | 2017 | 365 | 0.120 |
Why?
|
| Cost Control | 1 | 2017 | 627 | 0.120 |
Why?
|
| Risk Adjustment | 1 | 2018 | 600 | 0.120 |
Why?
|
| Drug Prescriptions | 1 | 2024 | 1669 | 0.120 |
Why?
|
| Chronic Disease | 2 | 2013 | 9310 | 0.120 |
Why?
|
| United States | 10 | 2024 | 72292 | 0.120 |
Why?
|
| Growth Charts | 1 | 2015 | 60 | 0.120 |
Why?
|
| Logistic Models | 3 | 2022 | 13248 | 0.120 |
Why?
|
| Attitude to Computers | 1 | 2015 | 195 | 0.110 |
Why?
|
| Drug Approval | 1 | 2021 | 812 | 0.110 |
Why?
|
| Drug Hypersensitivity | 1 | 2023 | 917 | 0.110 |
Why?
|
| Hospital Bed Capacity | 1 | 2015 | 206 | 0.110 |
Why?
|
| Long QT Syndrome | 1 | 2018 | 466 | 0.110 |
Why?
|
| Heart Diseases | 2 | 2022 | 2778 | 0.110 |
Why?
|
| Hypersensitivity | 1 | 2023 | 1167 | 0.110 |
Why?
|
| Withholding Treatment | 1 | 2018 | 615 | 0.110 |
Why?
|
| Neutropenia | 1 | 2018 | 885 | 0.110 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2022 | 1878 | 0.110 |
Why?
|
| Severity of Illness Index | 2 | 2021 | 15829 | 0.100 |
Why?
|
| United States Food and Drug Administration | 1 | 2021 | 1661 | 0.100 |
Why?
|
| Polymerase Chain Reaction | 1 | 2022 | 6074 | 0.100 |
Why?
|
| Antibodies, Neutralizing | 1 | 2022 | 1936 | 0.100 |
Why?
|
| Anticonvulsants | 1 | 2022 | 1910 | 0.100 |
Why?
|
| Faculty, Medical | 1 | 2020 | 1204 | 0.100 |
Why?
|
| Male | 14 | 2024 | 360402 | 0.100 |
Why?
|
| Infant, Premature, Diseases | 1 | 2017 | 710 | 0.090 |
Why?
|
| Critical Illness | 1 | 2024 | 2709 | 0.090 |
Why?
|
| Female | 14 | 2024 | 392203 | 0.090 |
Why?
|
| Risk Assessment | 3 | 2020 | 23974 | 0.090 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 3149 | 0.090 |
Why?
|
| Pandemics | 2 | 2021 | 8652 | 0.090 |
Why?
|
| Administration, Oral | 1 | 2018 | 4010 | 0.090 |
Why?
|
| Drug Administration Schedule | 1 | 2018 | 4845 | 0.090 |
Why?
|
| Child Welfare | 1 | 2014 | 521 | 0.090 |
Why?
|
| Insurance Claim Review | 1 | 2014 | 741 | 0.090 |
Why?
|
| Attitude of Health Personnel | 2 | 2015 | 3882 | 0.080 |
Why?
|
| Education, Medical, Continuing | 1 | 2014 | 825 | 0.080 |
Why?
|
| Child Health Services | 1 | 2014 | 644 | 0.080 |
Why?
|
| Evidence-Based Medicine | 1 | 2021 | 3680 | 0.080 |
Why?
|
| Hospitalization | 3 | 2023 | 10708 | 0.080 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2022 | 2252 | 0.070 |
Why?
|
| Registries | 2 | 2017 | 8209 | 0.070 |
Why?
|
| Program Development | 1 | 2013 | 1293 | 0.070 |
Why?
|
| Systems Integration | 1 | 2007 | 426 | 0.060 |
Why?
|
| Prevalence | 4 | 2017 | 15702 | 0.060 |
Why?
|
| Interdisciplinary Communication | 1 | 2010 | 928 | 0.060 |
Why?
|
| Clinical Competence | 1 | 2020 | 4790 | 0.060 |
Why?
|
| Socioeconomic Factors | 1 | 2018 | 7805 | 0.060 |
Why?
|
| Program Evaluation | 1 | 2013 | 2486 | 0.060 |
Why?
|
| Health Care Costs | 1 | 2017 | 3238 | 0.060 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 5838 | 0.050 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2010 | 1017 | 0.050 |
Why?
|
| Mental Health | 1 | 2017 | 3253 | 0.050 |
Why?
|
| Respiratory Tract Diseases | 1 | 2008 | 750 | 0.050 |
Why?
|
| Asthma | 1 | 2022 | 6234 | 0.050 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 1 | 2002 | 141 | 0.050 |
Why?
|
| Tennessee | 1 | 2002 | 119 | 0.050 |
Why?
|
| Respiration, Artificial | 2 | 2024 | 2630 | 0.050 |
Why?
|
| Insurance, Health | 1 | 2014 | 2495 | 0.050 |
Why?
|
| Metabolic Diseases | 1 | 2008 | 680 | 0.050 |
Why?
|
| Aspergillus | 1 | 2022 | 93 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2010 | 14649 | 0.050 |
Why?
|
| Transcription, Genetic | 2 | 2006 | 7583 | 0.050 |
Why?
|
| Glutamic Acid | 1 | 2006 | 1175 | 0.050 |
Why?
|
| Age Factors | 1 | 2017 | 18381 | 0.040 |
Why?
|
| Internship and Residency | 1 | 2020 | 5878 | 0.040 |
Why?
|
| DNA, Complementary | 1 | 2003 | 1989 | 0.040 |
Why?
|
| Penicillins | 1 | 2023 | 402 | 0.040 |
Why?
|
| Child, Hospitalized | 1 | 2021 | 182 | 0.040 |
Why?
|
| Professional Autonomy | 1 | 2020 | 171 | 0.040 |
Why?
|
| Emotional Intelligence | 1 | 2020 | 135 | 0.040 |
Why?
|
| Time Factors | 2 | 2018 | 39908 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2006 | 3776 | 0.040 |
Why?
|
| Kidney Diseases | 1 | 2008 | 2090 | 0.040 |
Why?
|
| Cloning, Molecular | 1 | 2003 | 4172 | 0.040 |
Why?
|
| Mental Disorders | 1 | 2017 | 6826 | 0.040 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2002 | 1936 | 0.030 |
Why?
|
| Massachusetts | 1 | 2008 | 8835 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2008 | 12043 | 0.030 |
Why?
|
| Genome | 1 | 2003 | 1737 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2018 | 41464 | 0.030 |
Why?
|
| Urban Population | 1 | 2002 | 2034 | 0.030 |
Why?
|
| Young Adult | 2 | 2024 | 59191 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2024 | 2218 | 0.030 |
Why?
|
| Gene Expression Profiling | 2 | 2006 | 9417 | 0.030 |
Why?
|
| Bacterial Proteins | 1 | 2006 | 3842 | 0.030 |
Why?
|
| New York | 1 | 2015 | 875 | 0.030 |
Why?
|
| Interpersonal Relations | 1 | 2020 | 1438 | 0.030 |
Why?
|
| Morbidity | 1 | 2017 | 1750 | 0.020 |
Why?
|
| Diagnosis-Related Groups | 1 | 2013 | 448 | 0.020 |
Why?
|
| Accreditation | 1 | 2014 | 473 | 0.020 |
Why?
|
| Patient-Centered Care | 1 | 2020 | 1419 | 0.020 |
Why?
|
| Obesity | 2 | 2023 | 12934 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2020 | 3017 | 0.020 |
Why?
|
| Adult | 2 | 2022 | 220995 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2008 | 26065 | 0.020 |
Why?
|
| International Classification of Diseases | 1 | 2013 | 912 | 0.020 |
Why?
|
| Data Collection | 1 | 2015 | 3316 | 0.020 |
Why?
|
| RNA Caps | 1 | 2003 | 73 | 0.010 |
Why?
|
| Expressed Sequence Tags | 1 | 2003 | 250 | 0.010 |
Why?
|
| Polyadenylation | 1 | 2003 | 115 | 0.010 |
Why?
|
| HIV Infections | 1 | 2008 | 17342 | 0.010 |
Why?
|
| Curriculum | 1 | 2014 | 3739 | 0.010 |
Why?
|
| Gene Library | 1 | 2003 | 1055 | 0.010 |
Why?
|
| Patient Discharge | 1 | 2013 | 3442 | 0.010 |
Why?
|
| Neoplasms | 1 | 2008 | 22131 | 0.010 |
Why?
|
| Genes | 1 | 2003 | 1823 | 0.010 |
Why?
|
| Organ Specificity | 1 | 2003 | 1964 | 0.010 |
Why?
|
| Databases, Genetic | 1 | 2003 | 1742 | 0.010 |
Why?
|
| Cluster Analysis | 1 | 2003 | 2703 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 39062 | 0.010 |
Why?
|
| Algorithms | 1 | 2014 | 14024 | 0.010 |
Why?
|
| Animals | 2 | 2022 | 168202 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2003 | 4739 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2003 | 22117 | 0.000 |
Why?
|
| Middle Aged | 1 | 2014 | 220603 | 0.000 |
Why?
|
| Mice | 1 | 2003 | 81368 | 0.000 |
Why?
|